Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Bell

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Journal of the National Cancer Institute|February 10, 2018
Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) TrialJanet Brown, Emma Rathbone, Samantha Hinsley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04)Emma J Rathbone, Janet E Brown, Helen C Marshall, et al.
Breast Cancer Research and Treatment|June 9, 2012
Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization ProgramMichael Bilous, Adrienne L Morey, Jane E Armes, et al.
JACC. Heart Failure|August 12, 2019
Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab CardiotoxicityShom Goel, Jia Liu, Hao Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myelomaH Miles Prince, Linda Mileshkin, Andrew Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2020
Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility StudyJames W F Catto, Kathryn Gordon, Michelle Collinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2012
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acidMiguel Martin, Richard Bell, Hugues Bourgeois, et al.
Anticancer Research|February 4, 2019
Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA TrialAmir Sonnenblick, Andrew Bailey, Beatrice Uziely, et al.
The New England Journal of Medicine|October 15, 2011
Breast-cancer adjuvant therapy with zoledronic acidRobert E Coleman, Helen Marshall, David Cameron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trialOtto Metzger-Filho, Marion Procter, Evandro de Azambuja, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Journal of the National Cancer Institute|February 10, 2018
Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) TrialJanet Brown, Emma Rathbone, Samantha Hinsley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04)Emma J Rathbone, Janet E Brown, Helen C Marshall, et al.
Breast Cancer Research and Treatment|June 9, 2012
Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization ProgramMichael Bilous, Adrienne L Morey, Jane E Armes, et al.
JACC. Heart Failure|August 12, 2019
Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab CardiotoxicityShom Goel, Jia Liu, Hao Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myelomaH Miles Prince, Linda Mileshkin, Andrew Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2020
Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility StudyJames W F Catto, Kathryn Gordon, Michelle Collinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2012
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acidMiguel Martin, Richard Bell, Hugues Bourgeois, et al.
Anticancer Research|February 4, 2019
Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA TrialAmir Sonnenblick, Andrew Bailey, Beatrice Uziely, et al.
The New England Journal of Medicine|October 15, 2011
Breast-cancer adjuvant therapy with zoledronic acidRobert E Coleman, Helen Marshall, David Cameron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trialOtto Metzger-Filho, Marion Procter, Evandro de Azambuja, et al.
Pageof 10